General MedicationsORALGeneric
TEGISON
ETRETINATE
Standard Dose
10MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: PRIORITY Marketing status: Discontinued
Summary
Approval overview TEGISON is listed in Drugs@FDA under application 019369 (NDA).
Review priority: PRIORITY Marketing status: Discontinued Active ingredient ETRETINATE Form and strength CAPSULE;ORAL - 10MG Sponsor ROCHE Submission history Latest submission status date: 1995-02-16 00:00:00.
Structured Monograph
Clinical summary
Approval overview TEGISON is listed in Drugs@FDA under application 019369 (NDA). Review priority: PRIORITY Marketing status: Discontinued Active ingredient ETRETINATE Form and strength CAPSULE;ORAL - 10MG Sponsor ROCHE Submission history Latest submission status date: 1995-02-16 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Discontinued
- • Review priority: PRIORITY
Interaction Notes
- No interaction notes stored yet.